Logo

Epigenomics to Identify, Analyze Biomarkers for J&J Cancer Program

Aug 07, 2006
NEW YORK (GenomeWeb News) - Epigenomics will use its differential methylation hybridization chip to help Johnson & Johnson Pharmaceutical Research & Development identify and analyze biomarkers for potential cancer drugs.
 
Terms of the agreement call for Epigenomics to receive an undisclosed upfront payment under the agreement.
 
Additional financial details were not disclosed.

Filed under

Microarrays & Multiplexing
microarrays
Breaking News
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.